Inhibition of dengue virus RNA synthesis by an adenosine nucleoside

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2932-2939

  Chen, Yen Liang ^a   Yin, Zheng ^a,c   Duraiswamy, Jeyaraj ^a   Schul, Wouter ^a   Lim, Chin Chin ^a   Liu, Boping ^a   Xu, Hao Ying ^a   Qing, Min ^a   Yip, Andy ^a   Wang, Gang ^a   Chan, Wai Ling ^a   Tan, Hui Pen ^a   Lo, Melissa ^a   Liung, Sarah ^a   Kondreddi, Ravinder Reddy ^a   Rao, Ranga ^a   Gu, Helen ^b   He, Handan ^b   Keller, Thomas H ^a   Shi, Pei Yong ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO 5 FLUORO 7H PYRROLO[2,3 D]PYRIMIDINE; 4 CHLORO 7H PYRROLO[2,3 D]PYRIMIDINE; 7 DEAZA 2' C ACETYLENE ADENOSINE; ADENINE; ADENOSINE KINASE; ALPHA DEXTRO 1,3,5 TRI O BENZOYL RIBOFURANOSE; CARBON 14; CYTOSINE; GUANOSINE; NUCLEOSIDE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ADENOSINE; ANTIVIRUS AGENT; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DENGUE; DENGUE VIRUS; DRUG STRUCTURE; DRUG SYNTHESIS; HAMSTER; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RNA SYNTHESIS; STRUCTURE ACTIVITY RELATION; VIREMIA; VIRUS INHIBITION; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WISTAR RAT;

ADENOSINE; ADENOSINE KINASE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; DENGUE VIRUS; HUMANS; MALE; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; RNA, VIRAL;

EID: 77953742065     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00140-10     Document Type: Article

References (36)

1. Ackermann, M., and R. Padmanabhan. 2001. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J. Biol. Chem. 276:39926-39937.
2. Bio, M. M., F. Xu, M. Waters, J. M. Williams, K. A. Savary, C. J. Cowden, C. Yang, E. Buck, Z. J. Song, D. M. Tschaen, R. P. Volante, R. A. Reamer, and E. J. Grabowski. 2004. Practical synthesis of a potent hepatitis C virus RNA replication inhibitor. J. Org. Chem. 69:6257-6266.
3. Carroll, S. S., S. Ludmerer, L. Handt, K. Koeplinger, N. R. Zhang, D. Graham, M. E. Davies, M. MacCoss, D. Hazuda, and D. B. Olsen. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 53:926-934.
4. Carroll, S. S., and D. B. Olsen. 2006. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 6:17-29.
5. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
6. Cristalli, G., S. Costanzi, C. Lambertucci, G. Lupidi, S. Vittori, R. Volpini, and E. Camaioni. 2001. Adenosine deaminase: functional implications and different classes of inhibitors. Med. Res. Rev. 21:105-128.
7. De Clercq, E., and J. Neyts. 2009. Antiviral agents acting as DNA or RNA chain terminators. Handb. Exp. Pharmacol. 2009(189):53-84.
8. Egloff, M. P., D. Benarroch, B. Selisko, J. L. Romette, and B. Canard. 2002. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21:2757-2768.
9. Eldrup, A. B., C. R. Allerson, C. F. Bennett, S. Bera, B. Bhat, N. Bhat, M. R. Bosserman, J. Brooks, C. Burlein, S. S. Carroll, P. D. Cook, K. L. Getty, M. MacCoss, D. R. McMasters, D. B. Olsen, T. P. Prakash, M. Prhavc, Q. Song, J. E. Tomassini, and J. Xia. 2004. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47:2283-2295.
10. Falgout, B., R. H. Miller, and C. J. Lai. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J. Virol. 67:2034-2042. (Pubitemid 23088377)
11. Gubler, D., G. Kuno, and L. Markoff. 2007. Flaviviruses, p. 1153-1253. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed., vol. 1. Lippincott William & Wilkins, Philadelphia, PA.
12. Harry-O'kuru, R. E., J. M. Smith, and M. S. Wolfe. 1997. A short, flexible route toward 2′-C-branched ribonucleosides. J. Org. Chem. 62:1754-1759.
13. Klumpp, K., G. Kalayanov, H. Ma, S. Le Pogam, V. Leveque, W. R. Jiang, N. Inocencio, A. De Witte, S. Rajyaguru, E. Tai, S. Chanda, M. R. Irwin, C. Sund, A. Winqist, T. Maltseva, S. Eriksson, E. Usova, M. Smith, A. Alker, I. Najera, N. Cammack, J. A. Martin, N. G. Johansson, and D. B. Smith. 2008. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J. Biol. Chem. 283:2167-2175.
14. Klumpp, K., V. Leveque, S. Le Pogam, H. Ma, W. R. Jiang, H. Kang, C. Granycome, M. Singer, C. Laxton, J. Q. Hang, K. Sarma, D. B. Smith, D. Heindl, C. J. Hobbs, J. H. Merrett, J. Symons, N. Cammack, J. A. Martin, R. Devos, and I. Najera. 2006. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281:3793-3799.
15. Leary, J. J., R. Wittrock, R. T. Sarisky, A. Weinberg, and M. J. Levin. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46:762-768.
16. Lo, L., M. Tilgner, K. Bernard, and P.-Y. Shi. 2003. Functional analysis of mosquito-borne flavivirus conserved sequence elements within 3′ untranslated region of West Nile virus using a reporting replicon that differentiates between viral translation and RNA replication. J. Virol. 77:10004-10014.
17. Lopez, J., A. Samtodrian, C. Campas, and J. Gil. 2003. 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMPactivated protein kinase is not involved. Biochem. J. 370:1027-1032. (Pubitemid 36399097)
18. Maj, M. C., B. Singh, and R. S. Gupta. 2000. Structure-activity studies on mammalian adenosine kinase. Biochem. Biophys. Res. Commun. 275:386-393.
19. McGuigan, C., D. Cahard, H. M. Sheeka, E. De Clercq, and J. Balzarini. 1996. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem. 39:1748-1753.
20. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
21. Ng, C. Y., F. Gu, W. Y. Phong, Y. L. Chen, S. P. Lim, A. Davidson, and S. G. Vasudevan. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76:222-231.
22. Noble, C. G., Y. L. Chen, H. Dong, F. Gu, S. P. Lim, W. Schul, Q. Y. Wang, and P. Y. Shi. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res. 85:450-462.
23. Perrone, P., F. Daverio, R. Valente, S. Rajyaguru, J. A. Martin, V. Leveque, S. Le Pogam, I. Najera, K. Klumpp, D. B. Smith, and C. McGuigan. 2007. First example of phosphoramidate approach applied to a 4′-substituted purine nucleoside (4′-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J. Med. Chem. 50:5463-5470.
24. Perrone, P., G. M. Luoni, M. R. Kelleher, F. Daverio, A. Angell, S. Mulready, C. Congiatu, S. Rajyaguru, J. A. Martin, V. Leveque, S. Le Pogam, I. Najera, K. Klumpp, D. B. Smith, and C. McGuigan. 2007. Application of the phosphoramidate ProTide approach to 4′-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem. 50:1840-1849.
25. Puig-Basagoiti, F., T. S. Deas, P. Ren, M. Tilgner, D. M. Ferguson, and P.-Y. Shi. 2005. High-throughput assays using luciferase-expressing replicon, virus-like particle, and full-length virus for West Nile virus drug discovery. Antimicrob. Agent. Chemother. 49:4980-4988.
26. Puig-Basagoiti, F., M. Tilgner, B. M. Forshey, S. M. Philpott, N. G. Espina, D. E. Wentworth, S. J. Goebel, P. S. Masters, B. Falgout, P. Ren, D. M. Ferguson, and P.-Y. Shi. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320-1329.
27. Ray, D., A. Shah, M. Tilgner, Y. Guo, Y. Zhao, H. Dong, T. Deas, Y. Zhou, H. Li, and P.-Y. Shi. 2006. West Nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J. Virol. 80:8362-8370.
28. Sabini, E., S. Hazra, S. Ort, M. Konrad, and A. Lavie. 2008. Structural basis for substrate promiscuity of dCK. J. Mol. Biol. 378:607-621.
29. Schul, W., W. Liu, H. Y. Xu, M. Flamand, and S. G. Vasudevan. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195:665-674.
30. Shi, P. Y., M. Tilgner, M. K. Lo, K. A. Kent, and K. A. Bernard. 2002. Infectious cDNA clone of the epidemic West Nile virus from New York City. J. Virol. 76:5847-5856.
31. Shresta, S., K. L. Sharar, D. M. Prigozhin, P. R. Beatty, and E. Harris. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-10217.
32. Tan, B. H., J. Fu, R. J. Sugrue, E. H. Yap, Y. C. Chan, and Y. H. Tan. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216:317-325.
33. Wang, Q. Y., S. J. Patel, E. Vangrevelinghe, H. Y. Xu, R. Rao, D. Jaber, W. Schul, F. Gu, O. Heudi, N. L. Ma, M. K. Poh, W. Y. Phong, T. H. Keller, E. Jacoby, and S. G. Vasudevan. 2009. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 53:1823-1831.
34. Wengler, G., and G. Wengler. 1991. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 184:707-715.
35. Wengler, G., and G. Wengler. 1993. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273.
36. Yin, Z., Y.-L. Chen, W. Schul, Q.-Y. Wang, F. Gu, J. Duraiswamy, R. R. Kondreddi, P. Niyomrattanakit, S. B. Lakshminarayana, A. Goh, H. Y. Xu, W. Liu, B. Liu, J. Y. H. Lim, C. Y. Ng, M. Qing, C. C. Lim, A. Yip, G. Wang, W. L. Chan, H. P. Tan, K. Lin, B. Zhang, G. Zou, K. A. Bernard, C. Garrett, K. Beltz, M. Dong, M. Weaver, H. He, A. Pichota, V. Dartois, T. H. Keller, and P.-Y. Shi. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 106:20435-20439.